Company Overview and News
The FBM KLCI closed 15.79 points higher to 1,753.07, making it the best-performing index yesterday. The index has been on an upward trend since last week, after it fell to its 18-month low of 1,663.86 points on July 6.
1155 1023 4863 PBLOF MLYBY 6888 MLYNF AXXTF MYTEF 1295 CIMDF
KUALA LUMPUR (July 18): The FBM KLCI reversed its earlier losses and rose 0.31% at midday break, tracking gains at most Asian markets.
HLFBF 7172 PBLOF 7053 1082 7087 1295 9334 7123 0143 4863 0156 8613 0026 6888 5819 AXXTF MYTEF 2836
The market rebounded last week on rebounds in Asian markets and the central bank’s move not to raise the overnight policy rate. However, the ringgit weakened and commodity prices continued to fall. Weakening ringgit caused foreign institutions to continue selling. Nevertheless, local market participants supported the market and the FBM KLCI increased 3.5% in a week to 1,721.93 points last Friday. The index continued to increase this week and closed at 1,737.
1023 PNADF 6888 AXXTF PNAGF 6033 CIMDF
KUALA LUMPUR, July 16 — Public Investment Bank Bhd has reiterated a “neutral” call on telecommunications giant Axiata Group, on the prospect of its unit selling a 89 per cent shareholding in Multinet Pakistan Pte Ltd (Multinet Pakistan).
KUALA LUMPUR: IHH Healthcare Bhd said it is confident in its move to expand its footprint in India, following the acceptance of its bid to acquire a controlling stake in Fortis Healthcare Ltd.
5225 FORTIS 6888 532915 RELIGARE AXXTF FORTISMLR Q0F IHHHF 532843 523696
KUALA LUMPUR: Axiata Group Bhd ’s (Axiata) wholly owned unit Axiata Investments (Labuan) Ltd (AIL) has entered into an agreement with Adnan Asdar Ali (AAA) for the divestment of AIL’s 89% stake in Multinet Pakistan Pte Ltd for US$1 on a cash-free and debt-free basis.
6888 AXXTF BSMAF 1818
PRIME Minister Tun Dr Mahathir Mohamad commanded the support of the majority in forming a new Malaysia. A sizeable number in government-linked companies (GLCs) were and are still with the 93-year-old prime minister in his mission to reform the government and reduce excesses.
BSTHY 5347 5225 6888 TNABY AXXTF TNABF Q0F 2771 IHHHF
KUALA LUMPUR (July 13): The FBM KLCI rose 0.74% at midday break today, tracking gains at most regional markets, lifted by factors including key heavyweight index-linked stocks.
7052 UPBMF 5681 9679 2089 CIMDF 1023 3204 4863 5347 3867 0026 TNABY 6888 4723 AXXTF MYTEF TNABF GEBHF
IF Telekom Malaysia Bhd can keep its minimum RM700 million dividend promise, the stock will be oversold and the company undervalued. Yet the odds are stacked against the company rebounding in the near term due to uncertainties on multiple fronts. These uncertainties need to clear up before investors find TM appealing again, experts say.
KUALA LUMPUR (July 11): The FBM KLCI pared some of its losses at midday break today, and moved above the 1,680-point level.
PBLOF 7113 BATS TPGVF 4162 1295 7153 9334 5199 3204 5347 3301 7668 TNABY AXXTF HIPEF GEBHF SPMXF 1163 0131 TGLVY SPMXY 0026 6888 1899 TNABF
The market failed to rebound last week despite finding some support two weeks ago. Market sentiment was still bearish on extended US-China trade war. Asian markets were the main casualties. The FBM KLCI fell 1.6% in a week to 1,663.86 points last Friday. The index rebounded this week and closed at 1,687.13 points yesterday.
4863 6888 AXXTF MYTEF 7277
KUALA LUMPUR (July 11): The FBM KLCI fell 0.37% at mid-morning today as the U.S. re-ignited fears of a larger scale trade war with China after announcing it would impose added tariffs on Chinese imports.
7113 5681 TPGVF BATS 4162 1163 7153 TGLVY 7668 6888 AXXTF BSMAF 1818
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...